Advertisement

Breast Cancer Research and Treatment

, Volume 149, Issue 2, pp 525–536 | Cite as

Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis

  • María de PedroEmail author
  • Sara Baeza
  • María-Teresa Escudero
  • Trinidad Dierssen-Sotos
  • Inés Gómez-Acebo
  • Marina Pollán
  • Javier Llorca
Epidemiology

Abstract

Evidence on non-steroidal anti-inflammatory drugs (NSAID) use and breast cancer risk shows a slightly protective effect of these drugs, but previous studies lack randomized clinical trial results and present high heterogeneity in exposure measurement. This systematic review and meta-analysis widens the knowledge about NSAID use and breast cancer risk, updating the information from the last meta-analysis, focusing on evidence on specific effects of COX-2 inhibitors and differential expression patterns of hormonal receptors. A PubMed-database search was conducted to include all entries published with the keywords “BREAST CANCER NSAID ANTI-INFLAMMATORY” until 10/24/2013 providing original results from cohort studies, case–control studies, or randomized clinical trials with at least one reported relative risk (RR) or odds ratio (OR) on the association between any NSAID use and incidence of invasive breast cancer. This resulted in 49 publications, from which the information was retrieved about type of study, exposure characteristics, breast cancer characteristics, and breast cancer-NSAID association. Meta-analyses were performed separately for case–control and cohort studies and for different hormone-receptor status. NSAID use reduced invasive breast cancer risk by about 20 %. A similar effect was found for aspirin, acetaminophen, COX-2 inhibitors and, to a lesser extent, ibuprofen. The effect of aspirin was similar in preventing hormone-receptor-positive breast cancer. This meta-analysis suggests a slightly protective effect of NSAIDs-especially aspirin and COX-2 inhibitors- against breast cancer, which seems to be restricted to ER/PR+tumors.

Keywords

Anti-inflammatory drugs NSAID Aspirin Ibuprofen COX-2 inhibitor Breast cancer 

Notes

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Carter CA, Milholland RJ, Shea W, Ip MM (1983) Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res 43(8):3559–3562PubMedGoogle Scholar
  2. 2.
    Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90(6):455–460PubMedCrossRefGoogle Scholar
  3. 3.
    Shiff SJ, Rigas B (1999) The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 190(4):445–450PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18(55):7908–7916PubMedCrossRefGoogle Scholar
  5. 5.
    Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94(4):252–266PubMedCrossRefGoogle Scholar
  7. 7.
    Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D (2007) U.S. preventive services task force. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann Intern Med 146(5):365–375PubMedCrossRefGoogle Scholar
  8. 8.
    Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D (2007) U.S. preventive services task force. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann Intern Med 146(5):376–389PubMedCrossRefGoogle Scholar
  9. 9.
    Harris RE, Alshafie GA, Seibert K (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 20(8):2101–2103Google Scholar
  10. 10.
    Harris RE, Beebe-Donk J, Doss H, Burr Doss D (2005) Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 13(4):559–583PubMedGoogle Scholar
  11. 11.
    Howe LR (2007) Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 9(4):210PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Singh-Ranger G, Salhab M, Mokbel K (2008) The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat 109(2):189–198PubMedCrossRefGoogle Scholar
  13. 13.
    Howe LR, Lippman SM (2008) Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. J Natl Cancer Inst 100(20):1420–1423PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M (2005) Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 5:159PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Harris RE, Namboodiri K, Stellman SD, Wynder EL (1995) Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med 24(2):119–120PubMedCrossRefGoogle Scholar
  16. 16.
    Harris R, Namboodiri K, Farrar W (1995) Epidemiologic-study of nonsteroidal antiinflammatory drugs and breast-cancer. Oncol Rep 2(4):591–592PubMedGoogle Scholar
  17. 17.
    Rosenberg L (1995) Nonsteroidal anti-inflammatory drugs and cancer. Prev Med 24(2):107–109PubMedCrossRefGoogle Scholar
  18. 18.
    Harris RE, Namboodiri KK, Farrar WB (1996) Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7(2):203–205PubMedCrossRefGoogle Scholar
  19. 19.
    Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A, Shea S (1998) Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomark Prev 7(10):869–873Google Scholar
  20. 20.
    Coogan PF, Rao SR, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S (1999) The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 29(2):72–76PubMedCrossRefGoogle Scholar
  21. 21.
    Langman MJ, Cheng KK, Gilman EA, Lancashire RJ (2000) Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 320(7250):1642–1646PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Cotterchio M, Kreiger N, Sloan M, Steingart A (2001) Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomark Prev 10(11):1213–1217Google Scholar
  23. 23.
    Meier CR, Schmitz S, Jick H (2002) Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22(3):303–309PubMedCrossRefGoogle Scholar
  24. 24.
    Moorman PG, Grubber JM, Millikan RC, Newman B (2003) Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 14(10):915–922PubMedCrossRefGoogle Scholar
  25. 25.
    Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neugut AI (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291(20):2433–2440PubMedCrossRefGoogle Scholar
  26. 26.
    Swede H, Mirand AL, Menezes RJ, Moysich KB (2005) Association of regular aspirin use and breast cancer risk. Oncology 68(1):40–47PubMedCrossRefGoogle Scholar
  27. 27.
    Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L (2005) Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the case–control surveillance study revisited. Am J Epidemiol 162(2):165–170PubMedCrossRefGoogle Scholar
  28. 28.
    Harris RE, Beebe-Donk J, Alshafie GA (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 30(6):27CrossRefGoogle Scholar
  29. 29.
    Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM (2006) Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res 8(6):R71PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Vogel U, Christensen J, Nexø BA, Wallin H, Friis S, Tjønneland A (2007) Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 28(2):427–434PubMedCrossRefGoogle Scholar
  31. 31.
    Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS (2007) Long-term aspirin use and mortality in women. Arch Intern Med 167(6):562–572PubMedCrossRefGoogle Scholar
  32. 32.
    Davis S, Mirick DK (2007) Medication use and the risk of breast cancer. Eur J Epidemiol 22(5):319–325PubMedCrossRefGoogle Scholar
  33. 33.
    Kirsh VA, Kreiger N, Cotterchio M, Sloan M, Theis B (2007) Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol 166(6):709–716PubMedCrossRefGoogle Scholar
  34. 34.
    Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, Baumgartner KB, Wolff RR (2007) IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomark Prev 16(4):747–755CrossRefGoogle Scholar
  35. 35.
    Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, Edge SB, Kallakury BV, Marian C, Trevisan M, Shields PG, Freudenheim JL (2010) Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York exposures and breast cancer (WEB) Study. Cancer Causes Control 21(9):1503–1512PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Cronin-Fenton DP, Pedersen L, Lash TL, Friis S, Baron JA, Sørensen HT (2010) Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Res 12(2):R15PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Ashok V, Dash C, Rohan TE, Sprafka JM, Terry PD (2011) Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast 20(1):66–70PubMedCrossRefGoogle Scholar
  38. 38.
    Brasky TM, Bonner MR, Moysich KB, Ochs-Balcom HM, Marian C, Ambrosone CB, Nie J, Tao MH, Edge SB, Trevisan M, Shields PG, Freudenheim JL (2011) Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York exposures and breast cancer (WEB) study. Breast Cancer Res Treat 126(1):157–165PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, Edge SB, Kallakury BV, Marian C, Goerlitz DS, Trevisan M, Shields PG, Freudenheim JL (2011) Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control 22(7):965–975PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Vinogradova Y, Coupland C, Hippisley-Cox J (2011) Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies. Br J Cancer 105(3):452–459PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Jonsson F, Yin L, Lundholm C, Smedby KE, Czene K, Pawitan Y (2013) Low-dose aspirin use and cancer characteristics: a population-based cohort study. Br J Cancer 109(7):1921–1925PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Ou SM, Chen YT, Chao PW, Lee YJ, Liu CJ, Yeh CM, Chen TJ, Chen TW, Yang WC, Li SY (2013) Nonsteroidal anti-inflammatory drug use is associated with cancer risk reduction in chronic dialysis patients. Kidney Int 84(1):198–205PubMedCrossRefGoogle Scholar
  43. 43.
    Friedman GD, Ury HK (1980) Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 65(4):723–733PubMedGoogle Scholar
  44. 44.
    Paganini-Hill A, Chao A, Ross RK, Henderson BE (1989) Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 299(6710):1247–1250PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53(6):1322–1327PubMedGoogle Scholar
  46. 46.
    Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5(2):138–146PubMedCrossRefGoogle Scholar
  47. 47.
    Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA (1996) Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88(14):988–993PubMedCrossRefGoogle Scholar
  48. 48.
    Harris RE, Kasbari S, Farrar WB (1999) Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 6(1):71–73PubMedGoogle Scholar
  49. 49.
    Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA (2000) Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 83(1):112–120PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Friis S, Nielsen GL, Mellemkjaer L, McLaughlin JK, Thulstrup AM, Blot WJ, Lipworth L, Vilstrup H, Olsen JH (2002) Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer 97(1):96–101PubMedCrossRefGoogle Scholar
  51. 51.
    Johnson TW, Anderson KE, Lazovich D, Folsom AR (2002) Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomark Prev 11(12):1586–1591Google Scholar
  52. 52.
    Friis S, Sørensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003) A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88(5):684–688PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A (2003) Women’s health initiative. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the women’s health initiative. Cancer Res 63(18):6096–6101PubMedGoogle Scholar
  54. 54.
    Sørensen HT, Friis S, Nørgård B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA (2003) Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88(11):1687–1692PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E (2004) Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24(5B):3177–3184PubMedGoogle Scholar
  56. 56.
    García Rodríguez LA, González-Pérez A (2004) Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 91(3):525–529PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Jacobs EJ, Thun MJ, Connell CJ, Rodriguez C, Henley SJ, Feigelson HS, Patel AV, Flanders WD, Calle EE (2005) Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large US cohort. Cancer Epidemiol Biomark Prev 14(1):261–264Google Scholar
  58. 58.
    Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H, Peel D, Pinder R, Purdie DM, Reynolds P, Stram D, West D, Wright WE, Ziogas A, Ross RK (2005) Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97(11):805–812PubMedCrossRefGoogle Scholar
  59. 59.
    Gallicchio L, McSorley MA, Newschaffer CJ, Thuita LW, Huang HY, Hoffman SC, Helzlsouer KJ (2006) Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 106(7):1443–1452PubMedCrossRefGoogle Scholar
  60. 60.
    Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ (2007) Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 121(1):211–215PubMedCrossRefGoogle Scholar
  61. 61.
    Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN (2007) Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 166(10):1150–1158PubMedCrossRefGoogle Scholar
  62. 62.
    Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE (2007) A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99(8):608–615PubMedCrossRefGoogle Scholar
  63. 63.
    Bardia A, Ebbert JO, Vierkant RA, Limburg PJ, Anderson K, Wang AH, Olson JE, Vachon CM, Cerhan JR (2007) Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 99(11):881–889PubMedCrossRefGoogle Scholar
  64. 64.
    Friis S, Thomassen L, Sørensen HT, Tjønneland A, Overvad K, Cronin-Fenton DP, Vogel U, McLaughlin JK, Blot WJ, Olsen JH (2008) Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev 17(2):88–96PubMedCrossRefGoogle Scholar
  65. 65.
    Ready A, Velicer CM, McTiernan A, White E (2008) NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 109(3):533–543PubMedCrossRefGoogle Scholar
  66. 66.
    Gierach GL, Lacey JV Jr, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR, Brinton LA (2008) Nonsteroidal anti-inflammatory drugs and breast cancer risk in the national institutes of health-AARP diet and health study. Breast Cancer Res 10(2):R38PubMedCentralPubMedCrossRefGoogle Scholar
  67. 67.
    Siemes C, Visser LE, Coebergh JW, Hofman A, Uitterlinden AG, Stricker BH (2008) Protective effect of NSAIDs on cancer and influence of COX-2 C(-765G) genotype. Curr Cancer Drug Targets 8(8):753–764PubMedCrossRefGoogle Scholar
  68. 68.
    Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE (2009) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses’ Health Study II. Arch Intern Med 169(2):115–121PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, Limburg PJ, Anderson KE, Cerhan JR (2011) Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat 126(1):149–155PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L (2011) Regular aspirin use and breast cancer risk in US Black women. Cancer Causes Control 22(11):1553–1561PubMedCrossRefGoogle Scholar
  71. 71.
    Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE (2012) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol 30(28):3468–3477PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE (2005) Low-dose aspirin in the primary prevention of cancer: the women’s health study: a randomized controlled trial. JAMA 294(1):47–55PubMedCrossRefGoogle Scholar
  73. 73.
    Zhang SM, Cook NR, Manson JE, Lee IM, Buring JE (2008) Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer 98(5):989–991PubMedCentralPubMedCrossRefGoogle Scholar
  74. 74.
    Bulun SE, Lin Z, Imir G et al (2005) Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 57(3):359–383PubMedCrossRefGoogle Scholar
  75. 75.
    Asaga S, Jinno H, Sakata M, Kitajima M (2007) Current perspective of chemoprevention in breast cancer. Nihon Rinsho 65(Suppl 3):627–632PubMedGoogle Scholar
  76. 76.
    Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13(5):518–527PubMedCrossRefGoogle Scholar
  77. 77.
    Bosetti C, Gallus S, La Vecchia C (2006) Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17(7):871–888PubMedCrossRefGoogle Scholar
  78. 78.
    Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C (2012) Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 23(6):1403–1415PubMedCrossRefGoogle Scholar
  79. 79.
    González-Pérez A, García Rodríguez LA, López-Ridaura R (2003) Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3:28PubMedCentralPubMedCrossRefGoogle Scholar
  80. 80.
    Harris RE (2009) Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17(2):55–67PubMedCrossRefGoogle Scholar
  81. 81.
    Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84(9):1188–1192PubMedCentralPubMedCrossRefGoogle Scholar
  82. 82.
    Luo T, Yan HM, He P, Luo Y, Yang YF, Zheng H (2012) Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 131(2):581–587PubMedCrossRefGoogle Scholar
  83. 83.
    Mangiapane S, Blettner M, Schlattmann P (2008) Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf 17(2):115–124PubMedCrossRefGoogle Scholar
  84. 84.
    Takkouche B, Regueira-Méndez C, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100(20):1439–1447PubMedCrossRefGoogle Scholar
  85. 85.
    Tolentino Silva M, Freire Galvao T, Ricardo Zimmerman I, Gomes Pereira M, Cruz Lopes L (2012) Non-aspirin non-steroidal anti-inflammatory drugs for the primary chemoprevention of non-gastrointestinal cancer: summary of evidence. Curr Pharm Des 18(26):4047–4070CrossRefGoogle Scholar
  86. 86.
    Zhao YS, Zhu S, Li XW, Wang F, Hu FL, Li DD, Zhang WC, Li X (2009) Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat 117(1):141–150PubMedCrossRefGoogle Scholar
  87. 87.
    Brockwell SE, Gordon IR (2001) A comparison of statistical methods for metaanalysis. StatMed 20:825–840Google Scholar
  88. 88.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRefGoogle Scholar
  89. 89.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRefGoogle Scholar
  90. 90.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Brit Med J 315:629–634PubMedCentralPubMedCrossRefGoogle Scholar
  91. 91.
    Light RJ, Pillemer DB (1984) Summing up: The science of reviewing research. Harvard University Press, Cambridge, MAGoogle Scholar
  92. 92.
    Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463PubMedCrossRefGoogle Scholar
  93. 93.
    Jin ZC, Zhou XH, He J (2014) Statistical methods for dealing with publication bias in meta-analysis. Stat Med. doi: 10.1002/sim.6342 Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • María de Pedro
    • 1
    • 6
    Email author
  • Sara Baeza
    • 2
  • María-Teresa Escudero
    • 3
  • Trinidad Dierssen-Sotos
    • 4
  • Inés Gómez-Acebo
    • 4
  • Marina Pollán
    • 5
  • Javier Llorca
    • 4
  1. 1.Department of Obstetrics and GynecologyNuevo Belén University HospitalMadridSpain
  2. 2.Department of Obstetrics and GynecologyHospital Nuestra Señora de SonsolesÁvilaSpain
  3. 3.Department of Obstetrics and GynecologyMarqués de Valdecilla University HospitalSantanderSpain
  4. 4.Department of Preventive MedicineUniversity of Cantabria Medical School – IDIVAL, and CIBER Epidemiologia y Salud Publica (CIBERESP)SantanderSpain
  5. 5.Unit of Cancer EpidemiologyNational Center of Epidemiology (Institute of Health Carlos III) and CIBER Epidemiologia y Salud Publica (CIBERESP)MadridSpain
  6. 6.Facultad de Medicina (Medicina Preventiva)SantanderSpain

Personalised recommendations